MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Current Quarter	$-0.08	Next Quarter	$-0.06
Current Year	$-0.39	Next Year	$-0.36
QoQ Growth	+25.0%	YoY Growth	+7.7%
3Y EPS CAGR	-22.9%	Target Price	$7.00
Consensus	Buy	Upside	+319.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MXCT	$1.67	+2.45%	532.07K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MXCT	$1.67	+2.5%	532.07K
3
4
5
6

MXCT

MXCT

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get MaxCyte Inc. Data in Excel

Get MaxCyte Inc. Data in Excel